In vivo effects of tipifarnib plus etoposide on DNA damage and apoptosis in AML marrow blasts
| . | Clinical outcome . | |
|---|---|---|
| CR (n = 8) . | Non-CR (n = 25) . | |
| Median fold increase in total population γH2AX staining (day 8/day 0), (range) | 1.9 (0.6-3.1) | 0.98 (0.01-2.6) |
| ≥ 1.2-fold | 5/8 (62.5%) | 9/25 (36%) |
| ≥ 1.5-fold | 4/8 (50%) | 4/25 (16%) |
| Median fold increase in γH2AX staining intensity (“per cell”) (day 8/day 0), (range) | 1.13 (0.75-1.6) | 0.9 (0.5-1.2) |
| ≥ 1.2-fold | 3/8 (37.5%) | 1/25 (4%) |
| Median fold increase in sub2N DNA content (day 8/day 0), (range) | 2.0 (0.6-5.2) | 0.8 (0.2-19.8) |
| ≥ 1.2-fold | 5/6 (83%) | 10/21 (48%) |
| ≥ 1.5-fold | 4/6 (67%) | 8/21 (38%) |
| . | Clinical outcome . | |
|---|---|---|
| CR (n = 8) . | Non-CR (n = 25) . | |
| Median fold increase in total population γH2AX staining (day 8/day 0), (range) | 1.9 (0.6-3.1) | 0.98 (0.01-2.6) |
| ≥ 1.2-fold | 5/8 (62.5%) | 9/25 (36%) |
| ≥ 1.5-fold | 4/8 (50%) | 4/25 (16%) |
| Median fold increase in γH2AX staining intensity (“per cell”) (day 8/day 0), (range) | 1.13 (0.75-1.6) | 0.9 (0.5-1.2) |
| ≥ 1.2-fold | 3/8 (37.5%) | 1/25 (4%) |
| Median fold increase in sub2N DNA content (day 8/day 0), (range) | 2.0 (0.6-5.2) | 0.8 (0.2-19.8) |
| ≥ 1.2-fold | 5/6 (83%) | 10/21 (48%) |
| ≥ 1.5-fold | 4/6 (67%) | 8/21 (38%) |
Non-CR includes partial remission/hematologic improvement (PR/HI) and no remission (NR).